Compared to PRIMA-1, APR-246 exhibits stronger anti-tumor activity, counteracting the enhancement of the inflammatory tumor microenvironment caused by mutant p53, restoring immune surveillance and inhibiting immune evasion [133,134]. The gene discussed is TP53; the disease is neoplasm.